 <h1>Xolair Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>omalizumab</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about omalizumab. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Xolair.</p><h2>In Summary</h2><p><b>More frequent side effects include:</b> lower leg pain.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to omalizumab: subcutaneous powder for solution, subcutaneous solution</i></p><h3>Warning</h3><p class="blackboxWarning-title">Subcutaneous route (Powder for Solution; Solution)</p><p>AnaphylaxisAnaphylaxis, presenting as bronchospasm, hypotension, syncope, urticaria, and/or angioedema of the throat or tongue, has been reported to occur after administration of omalizumab. Anaphylaxis has occurred after the first dose of omalizumab, but also has occurred beyond 1 year after beginning treatment. Closely observe patients for an appropriate period of time after omalizumab administration and be prepared to manage anaphylaxis that can be life-threatening. Inform patients of the signs and symptoms of anaphylaxis and have them seek immediate medical care should symptoms occur.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, omalizumab (the active ingredient contained in Xolair) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<i>Check with your doctor or nurse immediately</i> if any of the following side effects occur while taking omalizumab:</p><p>
<i>Less common</i>
</p><ul>
<li>Blistering, crusting, irritation, itching, or reddening of the skin</li>
<li>body produces substance that can bind to drug making it less effective or cause side effects</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Cough</li>
<li>difficulty with swallowing</li>
<li>dizziness</li>
<li>fast heartbeat</li>
<li>hives, itching, or skin rash</li>
<li>malignant tumor</li>
<li>puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue</li>
<li>tightness in the chest</li>
<li>unusual tiredness or weakness</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Black, tarry stools</li>
<li>bleeding gums</li>
<li>blood in the urine or stools</li>
<li>chest pain</li>
<li>chills</li>
<li>difficulty in moving</li>
<li>fever</li>
<li>muscle pain or stiffness</li>
<li>pain in the joints</li>
<li>painful or difficult urination</li>
<li>pinpoint red spots on the skin</li>
<li>sore throat</li>
<li>sores, ulcers, or white spots on the lips or in the mouth</li>
<li>swollen glands</li>
<li>unusual bleeding or bruising</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of omalizumab may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Bleeding, blistering, burning, coldness, discoloration of skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site</li>
<li>body aches or pain</li>
<li>cold or flu-like symptoms</li>
<li>congestion</li>
<li>dryness or soreness of the throat</li>
<li>headache</li>
<li>hoarseness</li>
<li>leg pain</li>
<li>lumps</li>
<li>pain or tenderness around the eyes and cheekbones</li>
<li>stuffy or runny nose</li>
<li>voice changes</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Arm pain</li>
<li>cracked, dry, or scaly skin</li>
<li>earache</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Hair loss</li>
</ul><p>
<!-- end subcutaneous powder for solution, subcutaneous solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to omalizumab: subcutaneous powder for injection, subcutaneous solution</i></p><h3>General</h3><p>The more commonly reported side effects included injection site reactions, headache, and nasopharyngitis.<sup>[Ref]</sup></p><h3>Local</h3><p><b>Very common</b> (10% or more): Any injection site reaction, including pain, swelling, itching, redness, bruising, bleeding, induration, or mass (up to 45%), severe injection site reaction (up to 12%)</p>
<p><b>Uncommon</b> (0.1% to 1%): Arm swelling<sup>[Ref]</sup></p><p>In clinical trials, any injection site reaction occurred in 45% and 43% of patients given this drug and placebo, respectively; severe reactions occurred in 12% and 9%, respectively.<sup>[Ref]</sup></p><h3>Immunologic</h3><p>In clinical studies, viral infection occurred in 37% and 39% or patients given this drug or placebo, respectively.  Increased parasitic infections, compared to placebo, were not statistically significant.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Viral infection (up to 37%)</p>
<p><b>Uncommon</b> (0.1% to 1%): Moniliasis, parasitic infection</p>
<p><b>Rare</b> (0.01% to 0.1%): Anti-omalizumab antibody development</p>
<p><b>Postmarketing reports</b>: Serum sickness, allergic granulomatous angiitis (Churg-Strauss syndrome), lymphadenopathy<sup>[Ref]</sup></p><h3>Nervous system</h3><p>In clinical trials, headache occurred in 37% of patients given either this drug (n=716) or placebo (n=694); headache occurred very commonly in patients 6 to 12 years old.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Headache (up to 27%)</p>
<p><b>Common</b> (1% to 10%): Dizziness</p>
<p><b>Uncommon</b> (0.1% to 1%): Syncope, vasovagal syncope, somnolence, paresthesia</p>
<p><b>Frequency not reported</b>: Migraine, sinus headache<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Back pain (up to 13%)</p>
<p><b>Common</b> (1% to 10%): Arthralgia, myalgia, sprains, strains, extremity pain, fracture</p>
<p><b>Postmarketing reports</b>: Joint swelling<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Nasopharyngitis, sinusitis, viral upper respiratory infection (URI), URI</p>
<p><b>Uncommon</b> (0.1% to 1%): Pharyngitis, cough, allergic bronchospasm</p>
<p><b>Rare</b> (0.01% to 0.1%): Laryngoedema</p>
<p><b>Frequency not reported</b>: Asthma, oropharyngeal pain<sup>[Ref]</sup></p><p>In clinical trials with chronic idiopathic urticarial, patients reported nasopharyngitis 9.1%, 6.6%, and 7% in 150 mg, 300 mg, and placebo, respectively; sinusitis (1.1%, 4.9%, 2.1%), cough (1.1%, 2.2%,1.2%), and upper respiratory infection (11.1%, 3.4%, 2.1%) were also reported by patients, respectively.<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Dermatitis, pruritus</p>
<p><b>Uncommon</b> (0.1% to 1%): Skin rashes, flushing, photosensitivity</p>
<p><b>Postmarketing reports</b>: Alopecia, hair loss<sup>[Ref]</sup></p><h3>Other</h3><p>In clinical trials, fever occurred very commonly in patients 6 to 12 years old.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Fever, earache</p>
<p><b>Uncommon</b> (0.1% to 1%): Fatigue, post-injection phenomena<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>In clinical trials, upper abdominal pain was very common in patients 6 to 12 years old.  In clinical trials with chronic idiopathic urticarial, patients reported nausea 1.1%, 2.7%, and 2.5% of the time with 150 mg, 300 mg, and placebo, respectively.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Upper abdominal pain, nausea</p>
<p><b>Uncommon</b> (0.1% to 1%): Diarrhea, dyspepsia, gastroenteritis</p>
<p><b>Frequency not reported</b>: Toothache<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Urinary tract infection<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Uncommon</b> (0.1% to 1%): Urticaria</p>
<p><b>Rare</b> (0.01% to 0.1%): Anaphylactic reactions, angioedema</p>
<p><b>Postmarketing reports</b>: Anaphylactoid reactions<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Uncommon</b> (0.1% to 1%): Postural hypotension</p>
<p><b>Frequency not reported</b>: Peripheral edema, arterial thrombotic events (including transient ischemic attack, myocardial infarction, unstable angina, and cardiovascular death)</p>
<p><b>Postmarketing reports</b>: Hypotension, chest tightness<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Uncommon</b> (0.1% to 1%): Asymptomatic platelet decreases</p>
<p><b>Postmarketing reports</b>: Idiopathic severe thrombocytopenia, eosinophilic conditions<sup>[Ref]</sup></p><p>In clinical trials, 0.6% of patients developed decreased platelet counts below the normal laboratory range; these patients did not have associated bleeding episodes or decreased hemoglobin.<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Uncommon</b> (0.1% to 1%): Weight increases<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Frequency not reported</b>: Anxiety<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Xolair (omalizumab)." Genentech, South San Francisco, CA. </p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_3">3. Cerner Multum,  Inc. "Australian Product Information." O 0</p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>Is Xolair an immunosuppressant?</li>
<li>How long before Xolair starts working?</li>
<li>How does Xolair work?</li>
<li>Does Xolair cause weight gain?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about Xolair (omalizumab)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Patient Tips</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>169 Reviews</li>
<li>Drug class: selective immunosuppressants</li>
<li>FDA Alerts (2)</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Xolair &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Urticaria</li>
<li>Nasal Polyps</li>
<li>Asthma, Maintenance</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to omalizumab: subcutaneous powder for injection, subcutaneous solution</i></p><h3>General</h3><p>The more commonly reported side effects included injection site reactions, headache, and nasopharyngitis.<sup>[Ref]</sup></p><h3>Local</h3><p><b>Very common</b> (10% or more): Any injection site reaction, including pain, swelling, itching, redness, bruising, bleeding, induration, or mass (up to 45%), severe injection site reaction (up to 12%)</p><p><b>Uncommon</b> (0.1% to 1%): Arm swelling<sup>[Ref]</sup></p><p>In clinical trials, any injection site reaction occurred in 45% and 43% of patients given this drug and placebo, respectively; severe reactions occurred in 12% and 9%, respectively.<sup>[Ref]</sup></p><h3>Immunologic</h3><p>In clinical studies, viral infection occurred in 37% and 39% or patients given this drug or placebo, respectively.  Increased parasitic infections, compared to placebo, were not statistically significant.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Viral infection (up to 37%)</p><p><b>Uncommon</b> (0.1% to 1%): Moniliasis, parasitic infection</p><p><b>Rare</b> (0.01% to 0.1%): Anti-omalizumab antibody development</p><p><b>Postmarketing reports</b>: Serum sickness, allergic granulomatous angiitis (Churg-Strauss syndrome), lymphadenopathy<sup>[Ref]</sup></p><h3>Nervous system</h3><p>In clinical trials, headache occurred in 37% of patients given either this drug (n=716) or placebo (n=694); headache occurred very commonly in patients 6 to 12 years old.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Headache (up to 27%)</p><p><b>Common</b> (1% to 10%): Dizziness</p><p><b>Uncommon</b> (0.1% to 1%): Syncope, vasovagal syncope, somnolence, paresthesia</p><p><b>Frequency not reported</b>: Migraine, sinus headache<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Back pain (up to 13%)</p><p><b>Common</b> (1% to 10%): Arthralgia, myalgia, sprains, strains, extremity pain, fracture</p><p><b>Postmarketing reports</b>: Joint swelling<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Nasopharyngitis, sinusitis, viral upper respiratory infection (URI), URI</p><p><b>Uncommon</b> (0.1% to 1%): Pharyngitis, cough, allergic bronchospasm</p><p><b>Rare</b> (0.01% to 0.1%): Laryngoedema</p><p><b>Frequency not reported</b>: Asthma, oropharyngeal pain<sup>[Ref]</sup></p><p>In clinical trials with chronic idiopathic urticarial, patients reported nasopharyngitis 9.1%, 6.6%, and 7% in 150 mg, 300 mg, and placebo, respectively; sinusitis (1.1%, 4.9%, 2.1%), cough (1.1%, 2.2%,1.2%), and upper respiratory infection (11.1%, 3.4%, 2.1%) were also reported by patients, respectively.<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Dermatitis, pruritus</p><p><b>Uncommon</b> (0.1% to 1%): Skin rashes, flushing, photosensitivity</p><p><b>Postmarketing reports</b>: Alopecia, hair loss<sup>[Ref]</sup></p><h3>Other</h3><p>In clinical trials, fever occurred very commonly in patients 6 to 12 years old.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Fever, earache</p><p><b>Uncommon</b> (0.1% to 1%): Fatigue, post-injection phenomena<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>In clinical trials, upper abdominal pain was very common in patients 6 to 12 years old.  In clinical trials with chronic idiopathic urticarial, patients reported nausea 1.1%, 2.7%, and 2.5% of the time with 150 mg, 300 mg, and placebo, respectively.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Upper abdominal pain, nausea</p><p><b>Uncommon</b> (0.1% to 1%): Diarrhea, dyspepsia, gastroenteritis</p><p><b>Frequency not reported</b>: Toothache<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Urinary tract infection<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Uncommon</b> (0.1% to 1%): Urticaria</p><p><b>Rare</b> (0.01% to 0.1%): Anaphylactic reactions, angioedema</p><p><b>Postmarketing reports</b>: Anaphylactoid reactions<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Uncommon</b> (0.1% to 1%): Postural hypotension</p><p><b>Frequency not reported</b>: Peripheral edema, arterial thrombotic events (including transient ischemic attack, myocardial infarction, unstable angina, and cardiovascular death)</p><p><b>Postmarketing reports</b>: Hypotension, chest tightness<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Uncommon</b> (0.1% to 1%): Asymptomatic platelet decreases</p><p><b>Postmarketing reports</b>: Idiopathic severe thrombocytopenia, eosinophilic conditions<sup>[Ref]</sup></p><p>In clinical trials, 0.6% of patients developed decreased platelet counts below the normal laboratory range; these patients did not have associated bleeding episodes or decreased hemoglobin.<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Uncommon</b> (0.1% to 1%): Weight increases<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Frequency not reported</b>: Anxiety<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Xolair (omalizumab)." Genentech, South San Francisco, CA. </p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_3">3. Cerner Multum,  Inc. "Australian Product Information." O 0</p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>Is Xolair an immunosuppressant?</li>
<li>How long before Xolair starts working?</li>
<li>How does Xolair work?</li>
<li>Does Xolair cause weight gain?</li>
</ul><h2>More about Xolair (omalizumab)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Patient Tips</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>169 Reviews</li>
<li>Drug class: selective immunosuppressants</li>
<li>FDA Alerts (2)</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Xolair &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Urticaria</li>
<li>Nasal Polyps</li>
<li>Asthma, Maintenance</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>